LPTX LEAP THERAPEUTICS, INC.

Nasdaq leaptx.com


$ 0.62 $ 0.00 (0 %)    

Wednesday, 15-Oct-2025 06:47:17 EDT
QQQ $ 602.83 $ 0.00 (0 %)
DIA $ 464.91 $ 0.00 (0 %)
SPY $ 666.41 $ 0.00 (0 %)
TLT $ 91.02 $ 0.00 (0 %)
GLD $ 386.43 $ 0.00 (0 %)
$ 0.6209
$ 0.60
$ 0.62 x 20,500
$ 0.63 x 1,600
-- - --
$ 0.22 - $ 4.79
895,727
na
25.73M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-18-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-16-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 02-23-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-leap-therapeutics-down-9-in-pre-market-trading

Leap Therapeutics is trading lower in pre-market following a $58.9 million private placement led by Winklevoss Capital.

 leap-therapeutics-secures-589m-pipe-led-by-winklevoss-capital-for-9585m-shares-and-warrants-to-buy-719m-shares

Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

 leap-therapeutics-reports-updated-results-from-part-b-of-defiance-phase-2-study-of-sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-vs-bevacizumab-and-chemotherapy-for-advanced-microsatellite-stable-colorectal-cancer

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEG...

 leap-therapeutics-q1-eps-037-beats-038-estimate

Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0...

 hc-wainwright--co-reiterates-neutral-on-leap-therapeuticsto-neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) from Neutral to Neutral.

 penny-stock-leap-therapeutics-unveils-positive-data-from-experimental-combo-therapy-for-colorectal-cancer

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with on...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION